Lexicon Pharmaceuticals (LXRX) : Investors lapped up stocks on upticks to the tune of $0.34 million in the Fridays trading session. The trading value on downticks was comparatively at $0.15 million and the uptick to downtick ratio of 2.24 indicates continuous buying by the bulls. The net money flow into the stock was $0.19 million. Upticks saw transactions worth $0 clearly indicating buying by large investors. The total money flow for block trades stood at $0 million, which is a positive for the stock in the long-term. Lexicon Pharmaceuticals (LXRX) fell $0.14 during the day at $14.19, a drop of -0.98% over the previous days close. However, for the week, the stock is -0.07%, compared to the previous week.
The company Insiders own 5.4% of Lexicon Pharmaceuticals shares according to the proxy statements.
In a related news,The officer (VP, Finance & Accounting) of Lexicon Pharmaceuticals, Inc., Tessmer James F sold 1,500 shares at $15 on June 6, 2016. The Insider selling transaction had a total value worth of $22,500. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Lexicon Pharmaceuticals (NASDAQ:LXRX): stock was range-bound between the intraday low of $14.04 and the intraday high of $14.426 after having opened at $14.41 on Fridays session. The stock finally closed in the red at $14.41, a loss of -0.84%. The stock remained in the red for the whole trading day. The total traded volume was 344,663 shares. The stock failed to cross $14.426 in Fridays trading. The stocks closing price on Thursday was $14.33.
Lexicon Pharmaceuticals (LXRX) : During the past 4 weeks, traders have been relatively bearish on Lexicon Pharmaceuticals (LXRX), hence the stock is down -13.08% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.43% relative to the S&P 500. The stock has risen by 0.07% in the past week indicating that the buyers are active at lower levels, but the stock is down -13.2% in the past 4 weeks.
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Companys telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Companys sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.